LEADER 03358oam 2200613I 450 001 9910786960303321 005 20230803030142.0 010 $a0-429-06447-0 010 $a1-4398-7186-8 024 7 $a10.1201/b14751 035 $a(CKB)2670000000359640 035 $a(EBL)1186500 035 $a(SSID)ssj0000905660 035 $a(PQKBManifestationID)11530106 035 $a(PQKBTitleCode)TC0000905660 035 $a(PQKBWorkID)10926887 035 $a(PQKB)10862028 035 $a(MiAaPQ)EBC1186500 035 $a(Au-PeEL)EBL1186500 035 $a(CaPaEBR)ebr10700024 035 $a(CaONFJC)MIL501634 035 $a(OCoLC)843642698 035 $a(OCoLC)858015091 035 $a(EXLCZ)992670000000359640 100 $a20180331d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aRandomized phase II cancer clinical trials /$fSin-Ho Jung 210 1$aBoca Raton, Fla. :$cTaylor & Francis Group,$d2013. 215 $a1 online resource (236 p.) 225 1 $aChapman & Hall/CRC biostatistics series 300 $aDescription based upon print version of record. 311 $a1-4398-7185-X 320 $aIncludes bibliographical references. 327 $aFront Cover; Contents; Preface; Chapter 1 Introduction; Chapter 2 Single-Arm Phase II Trial Designs; Chapter 3 Inference on the Binomial Probability in Single-Arm Multistage Clinical Trials; Chapter 4 Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints; Chapter 5 Single-Arm Phase II Trials with Heterogeneous Patient Populations: Binary and Survival Outcomes; Chapter 6 Randomized Phase II Trials for Selection: No Prospective Control Arms; Chapter 7 Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (I): Two-Sample Binomial Test 327 $aChapter 8 Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (II): Fisher's Exact TestChapter 9 Randomized Phase II Trials with Heterogeneous Patient Populations: Stratified Fisher's Exact Test; Chapter 10 Randomized Phase II Clinical Trials Based on Survival Endpoints: Two-Sample Log-Rank Test; Chapter 11 Some Flexible Phase II Clinical Trial Designs; Back Cover 330 $aIn cancer research, a traditional phase II trial is designed as a single-arm trial that compares the experimental therapy to a historical control. This simple trial design has led to several adverse issues, including increased false positivity of phase II trial results and negative phase III trials. To rectify these problems, oncologists and biostatisticians have begun to use a randomized phase II trial that compares an experimental therapy with a prospective control therapy. Randomized Phase II Cancer Clinical Trials explains how to properly select and accurately use diverse statistical metho 410 0$aChapman & Hall/CRC biostatistics series (Unnumbered) 606 $aCancer$xResearch 606 $aClinical trials 615 0$aCancer$xResearch. 615 0$aClinical trials. 676 $a616.994060724 700 $aJung$b Sin-Ho.$01529504 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910786960303321 996 $aRandomized phase II cancer clinical trials$93773807 997 $aUNINA